Resource Library

Discover Kymera’s research and resources on our exciting platform, pipeline, and additional cutting-edge technologies.

  • Programs & Targets

  • Indications

  • Year

  • Resource Type/Format

  • Development Stage

Related Resources

May 3, 2022

STAT3 Degraders Inhibit Cellular Activation, Cytokine Production, and Th17 Development, Resulting in Profound Inhibition of Autoimmunity in the MOG-EAE Model of CNS Inflammation

The American Association of Immunologists (AAI) Immunology2022(TM)
Read More
May 3, 2022

Selective IRAK4 Degradation, Not Kinase Inhibition, Blocks TLR-activated NF-kB and p38 Signaling Leading to broad Cytokine Inhibition

The American Association of Immunologists (AAI) Immunology2022(TM)
Read More
October 28, 2021

Considerations for E3 Ligase Pairing and Screening of Immune-Inflammation Targets

4th Annual TPD Summit
Read More
October 27, 2021

Safety, PK and PD from Single Ascending Does Portion of KT-474 Phase 1 Trial in Healthy Volunteers

4th Annual TPD Summit
Hidradenitis Suppurativa (HS) Atopic Dermatitis (AD)
Read More
October 26, 2021

TPD Workshop: De-risking Clinical Development of a Novel Protein Degrader

4th Annual TPD Summit
Hidradenitis Suppurativa (HS) Atopic Dermatitis (AD)
Read More
September 21, 2021

Identification of Highly Potent and Selective Interleukin-1 Receptor Associates Kinase 4 (IRAK4) Degrader for the Treatment of Autoimmune Disease

European Protein Degradation Congress
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
Read More
May 10, 2021

IRAK4 Degradation Abrogates Cytokine Release and Improves Disease Endpoints in Murine Models of IL-33/36- as well as Th17-driven Inflammation

American Association of Immunologists’ Virtual IMMUNOLOGY2021™ Annual Meeting
Hidradenitis Suppurativa (HS) Atopic Dermatitis (AD)
Read More
May 3, 2021

Multiple Mediators of Inflammation Correlate with IRAK4 Expression in the Skin of Hidradenitis Suppurativa Patients and are Blocked by the IRAK4 Degrader KT-474 in TLR-activated Monocytes

Society for Investigative Dermatology (SID) 2021 Annual Meeting
Hidradenitis Suppurativa (HS) Atopic Dermatitis (AD)
Read More
November 3, 2020

IRAK4 Degrader to Take on Innate Immunity

Mullard, A. IRAK4 degrader to take on innate immunity. Nat Biotechnol 38, 1221–1223 (2020)
Hidradenitis Suppurativa (HS) Atopic Dermatitis (AD)
Read More
October 9, 2020

Interim results from non-interventional study to evaluate cutaneous and circulating biomarkers for a novel IRAK4-targeted therapeutic in patients with hidradenitis suppurativa

5th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)
Hidradenitis Suppurativa (HS)
Read More